Investor Webinar
05 December 2022
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Investor Webinar
Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces that Dr Arron Tolley, Chief Executive Officer, David Bunka, Chief Technical Officer and Jenny Cutler, Interim Chief Financial Officer, will be presenting a live ShareSoc webinar on 6 December 5:00pm GMT.
The event will provide an opportunity for investors to learn more about the Company, its technology and progress made since IPO in December 2021. No new information will be disclosed during the event.
Further details of the event, along with a registration form, are available here:
https://www.sharesoc.org/events/sharesoc-webinar-with-aptamer-group-apta06-december-2022/
- ENDS -
For further information, please contact:
Aptamer Group plc
Dr Arron Tolley +44 (0) 1904 217 404
Consilium Strategic Communications
Matthew Neal / Chris Welsh / Lucy Featherstone +44 (0) 20 3709 5700
aptamergroup@consilium-comms.com
About Aptamer Group plc
Aptamer Group develops custom affinity binders through its proprietary Optimer® platform to enable new approaches in therapeutics, diagnostics and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers through the use of its proprietary Optimer platform.
Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global antibody market is currently worth over $145.0 billion. Optimer binders are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists.
Aptamer Group has successfully delivered projects for global pharma companies, diagnostic development companies, and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses. Through the unique Optimer technology and processes, scientists and collaborators are enabled to make faster, more informed decisions that support discovery and development across the Life Sciences.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
COMPANIES COVERED:
Latest directors dealings
- 40 minutes ago BT Group
- 45 minutes ago Dunelm Group
- 52 minutes ago PZ Cussons
- 1 hour ago Aquila Energy Efficiency Trust (EUR)
- 1 hour ago London Stock Exchange Group